-
Evolutionary classification of protein domains: Unveiling protein functions and advancing drug discovery蛋白质域的进化分类：揭示蛋白质功能和推进药物发现
-
Advances in Protein and Polypeptide Drug Analytics蛋白质和多肽药物分析进展
-
Use of oxidized low-density lipoprotein receptor 1 (OLR1) gene or expressed protein as target in preparation of drug for treating colorectal cancer, where drug can inhibit expression of OLR1 gene or inhibit function of OLR1 protein, to inhibit progression of colorectal cancer使用氧化低密度脂蛋白受体1（OLR1）基因或表达蛋白作为靶点制备治疗结直肠癌的药物，该药物可抑制OLR1基因的表达或抑制OLR1蛋白的功能，从而抑制结直肠癌的进展
-
The Research Progress on Dynamic Covalent Bonding-based Nanocarriers for Protein Drug Delivery基于动态共价键的纳米载体在蛋白质药物递送中的研究进展
-
Recent Advances in Targeted Protein Degradation Molecular Glues as Anticancer Drugs靶向蛋白降解分子胶作为抗癌药物的最新进展
-
Advances in protein-protein interaction inhibitors (PPIs): drug discovery strategies.蛋白质-蛋白质相互作用抑制剂（PPIs）的进展：药物发现策略
-
Advances in Protein and Polypeptide Drug Analytics.蛋白质和多肽药物分析进展
-
Use of programmed death ligand 1 binding molecule in drug combination for improving stability of protein-drug conjugate preparations, and treating advanced or metastatic solid malignant tumor使用程序性死亡配体1结合分子进行药物联合治疗，以提高蛋白质-药物偶联体制剂的稳定性，并治疗晚期或转移性实体恶性肿瘤
-
A phase 1 dose escalation/expansion study of GSK5764227, a B7homolog 3 protein targeted antibody-drug conjugate, in combination with standard of care in patients with advanced solid tumors FreeGSK5764227（一种靶向B7同源物3蛋白的抗体-药物偶联物）联合标准治疗在晚期实体瘤患者中的I期剂量递增/扩展研究
-
A review on ribosomal protein S3 (RPS3): Roles in cancer and its resistance to drugs核糖体蛋白S3（RPS3）的研究：在癌症及其耐药性中的作用
-
A review on ribosomal protein S3 (RPS3): Roles in cancer and its resistance to drugs.核糖体蛋白S3（RPS3）的研究：在癌症及其耐药性中的作用
-
Advances in the Oral Delivery of Protein and Peptide Drugs蛋白质和多肽药物口服递送的进展
-
Treating and preventing progression of cancer e.g. gastric cancer includes administering anti-programmed cell death protein 1 antibody and anti-human epidermal growth factor receptor 2 antibody-drug conjugate and cytotoxic molecule治疗和预防癌症（例如胃癌）的进展包括施用抗程序性细胞死亡蛋白1抗体和抗人表皮生长因子受体2抗体-药物偶联物以及细胞毒性分子
-
CMC considerations of manufacturing site changes for marketed therapeutic recombinant protein drugs from regulatory review从监管审查角度看，已上市治疗用重组蛋白药物生产场地变更的CMC考量
-
New insights into protein-protein interaction modulators in drug discovery and therapeutic advance药物发现和治疗进展中蛋白质-蛋白质相互作用调节剂的新见解
-
Research Progress of Pseudo-Proteins as Drug Carriers假蛋白作为药物载体的研究进展
-
Leveraging Artificial Intelligence and Machine Learning for Characterizing Protein Corona, Nanobiological Interactions, and Advancing Drug Discovery利用人工智能和机器学习表征蛋白质冠、纳米生物相互作用并推进药物发现
-
Advancements in protein-based bionanocomposites for targeted and controlled drug delivery systems: A comprehensive review用于靶向和控制药物递送系统的蛋白质基生物纳米复合材料的进展：全面综述
-
ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I studyABBV-400，一种靶向c-Met蛋白的抗体-药物偶联物（ADC），在EGFR野生型（WT）非鳞状（NSQ）非小细胞肺癌（NSCLC）晚期患者中的研究：I期研究结果
-
Research Progress in Predicting Binding Affinity between Drug Molecules and Target Proteins药物分子与靶蛋白结合亲和力预测研究进展